<DOC>
	<DOCNO>NCT00258765</DOCNO>
	<brief_summary>Radical prostatectomy use treat early prostate cancer otherwise well men , follow later cancer relapse 1 4 case . This study aim see post-operative adjuvant therapy combination zoledronic acid docetaxel might help reduce relapse case . Patients randomize receive adjuvant combination therapy therapy . All patient monitor closely sign relapse treat appropriately conventional salvage therapy .</brief_summary>
	<brief_title>Adjuvant Docetaxel-Zoledronic Acid High-risk Early Prostate Cancer Following Prostatectomy .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Radical prostatectomy prostate cancer within last 2 month . Postoperative Kattan nomogram predict &gt; 25 % risk PSA relapse 5 year . 6week postoperative serum PSA &lt; 0.2ng/mL . Low level circulate prostate cancer cell blood , detect PCR amplification PSA mRNA 6 week postprostatectomy . Preoperative serum PSA level &gt; 20ng/ml . Clinical evidence metastases 6week postoperative visit . Prior treatment either ADT bisphosphonate therapy . Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery ( e.g.extraction , implant ) Other protocol define inclusion / exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>zoledronic acid</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>high risk</keyword>
	<keyword>PSA</keyword>
	<keyword>docetaxel</keyword>
</DOC>